Introducing a New Antifungal Surveillance Program: Analysis of Resistance to Antifungals (ARIA) and Expanded Mycology Services at IHMA
7.10.2021 17:00:00 EEST | Business Wire | Press release
International Health Management Associates (IHMA) has initiated a new antifungal resistance surveillance program, Analysis of Resistance to Antifungals (ARIA) to further the development of new antifungal agents and monitor the development of antifungal resistance.
ARIA collects and determines the antifungal susceptibility of clinically-relevant Candida spp., which includes the emerging C. auris, filamentous fungi, and also rarer molds from hospitals world-wide, including China and India. IHMA offers an option for biopharmaceutical companies to add new antifungal agents to the program.
The first presentation of ARIA data - Analysis of Resistance In Antifungals (ARIA) - Global Surveillance of Candida spp. Isolates, Including C. auris, in 2019 - will be made at the upcoming 10th Trends in Medical Mycology (TIMM-10), 8-11 October 2021, Aberdeen, Scotland.
The ARIA program greatly enhances IHMA's pre-clinical and clinical mycology capabilities at the European facility (Monthey, Switzerland) to profile new products, molecularly characterize antifungal resistance mechanisms, and serve as a central laboratory for clinical trials.
“IHMA is continuously looking for new ways to help clients progress with their new anti-infective agent programs. Our ability to adapt and add new capabilities shows our flexibility, dedication, and interest in assisting clients in the ongoing fight against antimicrobial resistance. The addition of mycology services augments our goal to support the biopharmaceutical industry by providing a suite of premier microbiology services to clients wishing to conduct antifungal studies on a global scale,” said Jack L. Johnson, President/CEO of IHMA.
About IHMA:
As the leading global microbiology service provider to the biopharmaceutical industry, IHMA utilizes its extensive laboratory and industry expertise to support efficient and effective anti-infective product development. IHMA is a premier provider of reference laboratory services to support anti-infective product discovery and development as well as the development of diagnostic devices that detect bacterial resistance to antimicrobial agents and new technologies as they emerge.
For more information, please visit IHMA’s website (www.ihma.com).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005044/en/
Contact information
Darcie Carpenter PhD CIC
Director Global Business Development
+1.530.577.5296
dcarpenter@ihma.com
Ian Morrissey MBA PhD FRSM
Chief Scientific & Development Officer
+44.01279.724929
imorrissey@ihma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pantheon Expands Middle East Presence With New Abu Dhabi Office and Senior Regional Appointment30.9.2026 13:56:00 EEST | Press release
Pantheon, a leading global private markets firm with approximately $84bn in assets under management, today announced the expansion of its presence in the Middle East with the opening of its first office in ADGM, the international financial center based in Abu Dhabi, alongside the appointment of Firas Mallah as Managing Director and Head of Middle East. Demand for access to private equity, infrastructure, and private credit strategies continues to build among sophisticated investors across the Middle East, who recognize Pantheon for its 40-year track record of innovation and expertise across primaries, secondaries and co-investment opportunities. Secondaries – pioneered by Pantheon in 1988 – remains a defining thread across the platform: alongside its long-established private equity secondaries business, Pantheon has among the industry's first and largest private credit and infrastructure secondaries franchises, making it a strong partner in that space across the GCC. These strategies a
34% of Global Consumers Say They Are Worse Off Financially Than a Year Ago as Households Adapt to a New Era of Permanent Uncertainty, NIQ Finds30.9.2026 13:45:00 EEST | Press release
With over a third (34%) of global consumers saying they are financially worse off than they were a year ago, and another third (30%) saying they are financially better off, consumers are no longer waiting for economic conditions to improve. Around the world, households are adapting to a future where volatility remains a persistent reality, creating increasingly different financial outcomes, spending priorities, and pathways to growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930542911/en/ NIQ's Consumer Outlook: Guide to 2027 These findings come from NielsenIQ’s (NYSE: NIQ) latest global Consumer Outlook survey of more than 21,000 respondents across 31 countries, combined with NIQ's measurement of real-world purchasing behavior. The research reveals that economic uncertainty is no longer a temporary disruption, but a defining feature of how consumers make decisions. Findings include: 34% of global consumers globally
Neutrogena ® , Aveeno ® , and Regaine ® Present New Scientific Evidence Demonstrating How Science-Backed Ingredients Support Healthy Skin and Hair30.9.2026 13:45:00 EEST | Press release
Neutrogena®, Aveeno®, and Regaine®* will present 12 new scientific data sets at the 35th European Academy of Dermatology and Venereology (EADV) Congress taking place September 30th through October 3rd in Vienna. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930489298/en/ New Neutrogena science showcased at EADV 2026 in Vienna, Austria Abstracts presented will share new evidence demonstrating how science-backed ingredients including niacinamide, trehalose, colloidal oat and 5% minoxidil can help address some of the most common skin and hair concerns consumers experience, including acne, oily skin, dry skin, hyperpigmentation, eczema, UV-related skin damage and androgenetic alopecia. The findings reinforce a growing body of evidence showing that innovative formulations can deliver benefits beyond traditional expectations by helping protect and strengthen the skin barrier, improve visible skin concerns, and support hair reg
Compass Pathways Appoints Kelley Boucher as Chief People Officer30.9.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced the appointment of Kelley Boucher as Chief People Officer, effective today. This appointment strengthens the Compass executive team as the company continues to scale in support of its mission to bring the first classic psychedelic treatment to the field of psychiatry. In this role, Ms. Boucher will oversee the Company’s people strategy, with an initial focus on guiding its planned evolution towards the launch of COMP360 psilocybin, subject to FDA approval, in the first half of 2027. "We are thrilled to welcome Kelley to our executive team at this pivotal moment in Compass’ journey. As we prepare for our NDA submission in the fourth quarter of this year, we are closer than ever to achieving our goal of introducing an entirely new treatment model in mental health care with COMP360 psilocybin," said Kabir Nath, Chief Executive Officer a
NIQ Expands Google Relationship with Meridian Integration into NIQ Cadence™30.9.2026 13:30:00 EEST | Press release
NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the expansion of its relationship with Google through the integration of Meridian, Google's open-source MMM framework, into NIQ Cadence™, NIQ's AI-native marketing effectiveness operating system. The strategic partnership gives marketers a single place to measure marketing performance and act on it, shortening the distance between insights and optimization. Marketing leaders are under growing pressure to prove the return on every media dollar, and traditional measurement has struggled to keep pace. In NIQ’s latest CMO Report, 74% of CMOs said they were under more scrutiny to prove marketing ROI, while just 9% felt they had adequate access to real-time insights. NIQ Cadence™ was built to help close the 65-point actionability gap between accountability and timeliness. Rather than treating measurement as a one-time event, the integration brings Meridian into NIQ Cadence™, a unified platform which brings data, models
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom